A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/35 (2006.01) A61K 31/335 (2006.01) A61K 31/351 (2006.01) A61K 31/445 (2006.01) A61K 31/452 (2006.01) A61K 31/4523 (2006.01) A61K 31/535 (2006.01) A61K 31/5377 (2006.01) A61K 31/665 (2006.01) A61K 31/67 (2006.01) C07C 233/62 (2006.01) C07D 309/14 (2006.01) C07D 313/08 (2006.01) C07D 337/08 (2006.01) C07D 407/12 (2006.01)
Patent
CA 2304959
This invention is to provide a pharmaceutical composition for antagonizing CCR5 which comprises a compound of formula (I) wherein R1 is an optionally substituted 5- to 6-membered ring; W is a divalent group of formula (a) or (b) wherein the ring A is an optionally substituted 5- to 6-membered aromatic ring, X is an optionally substituted C, N or O atom, and the ring B is an optionally substituted 5- to 7-membered ring; Z is a chemical bond or a divalent group; R2 is (1) an optionally substituted amino group in which a nitrogen atom may form a quaternary ammonium, (2) an optionally substituted nitrogen-containing heterocyclic ring group which may contain a sulfur atom or an oxygen atom as ring constituting atoms and wherein a nitrogen atom may form a quaternary ammonium, (3) a group binding through a sulfur atom or (4) a group of formula (II) wherein k is 0 or 1, and when k is 0, a phosphorus atom may form a phosphonium; and R5' and R6' are independently an optionally substituted hydrocarbon group, an optionally substituted hydroxy group or an optionally substituted amino group, and R5' and R6' may bind to each other to form a cyclic group together with the adjacent phosphorus atom, or a salt thereof.
L'invention concerne une composition pharmaceutique conçue pour s'opposer à CCR5 et contenant un composé représenté par la formule (1) dans laquelle R?1¿ représente un noyau éventuellement substitué de 5 à 6 éléments; W représente un groupe divalent de formule (a) ou (b) dans laquelle le noyau A est un noyau aromatique éventuellement substitué de 5 à 6 éléments, X représente un atome de C, N ou O éventuellement substitué et le noyau B est un noyau éventuellement substitué de 5 à 6 éléments; Z représente une liaison chimique ou un groupe divalent; R?2¿ représente un groupe amino éventuellement substitué dans lequel un atome d'azote peut constituer un ammonium quaternaire, etc., ou un de ses sels.
Aramaki Yoshio
Baba Masanori
Kanzaki Naoyuki
Kuroshima Ken-Ichi
Nishimura Osamu
Fetherstonhaugh & Co.
Takeda Chemical Industries Ltd.
LandOfFree
Pharmaceutical composition for antagonizing ccr5 comprising... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical composition for antagonizing ccr5 comprising..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical composition for antagonizing ccr5 comprising... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1848803